Lucid Diligence Brief - BioPharma

Conavi Medical Raises C$10 Million in Public Offering | Lucid Diligence Brief

Conavi Medical’s C$10M Financing Puts Novasight U.S. Adoption and Funding…


Lucid Diligence Brief - BioPharma

SERB–Hansa Idefirix Deal | Lucid Diligence Brief

SERB’s Idefirix rights acquisition from Hansa Biopharma sharpens its rare…


Lucid Diligence Brief - BioPharma

GSK Acquires Nuvalent to Expand Oncology Pipeline | Lucid Diligence Brief

GSK strengthens its oncology portfolio with Nuvalent acquisition, adding…


Lucid Diligence Brief - BioPharma

Secretome STM-01 Duchenne Cardiomyopathy | Lucid Diligence Brief

Secretome’s STM-01 faces Duchenne cardiomyopathy endpoint, CMC, and regulatory…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay

Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay Raises SERENA-6…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: SELLAS REGAL AML Phase 3 Nears Final Analysis

Lucid Diligence Brief: SELLAS approaches REGAL AML final analysis for…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Cullinan Therapeutics Gains FDA Orphan Drug Designation for CLN-049

Lucid Diligence Brief: Cullinan Therapeutics Receives FDA Orphan Drug…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Endologix's Pounce Acquisition

Lucid Diligence Brief: Endologix’s Pounce acquisition framed through clinical,…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition

Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Axoft $55 million Series A

Lucid Diligence Brief: Axoft $55 million Series A Professional audiences only.…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Teva to acquire Emalex Biosciences

Lucid Diligence Brief: Teva to acquire Emalex Biosciences Professional…


Privacy Preference Center